Apinya Leerapun

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

Oncology, Hepatology, Medicine +10

The Utility of Lens Culinaris Agglutinin-Reactive α-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: Evaluation in a United States Referral Population

Apinya Leerapun, Sri V. Suravarapu, John P. Bida et al. · Clinical Gastroenterology and Hepatology · 2007 · 151 citations · Full text

Hepatology, Medicine, Histopathology +8

Hypothyroidism: A Possible Risk Factor for Liver Cancer in Patients With No Known Underlying Cause of Liver Disease

Arvind Reddy, Chiranjeev Dash, Apinya Leerapun et al. · Clinical Gastroenterology and Hepatology · 2006 · 101 citations

Hepatology, Liver Physiology, Thyroid Disease +11

The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease

Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit et al. · Journal of Gastroenterology and Hepatology · 2021 · 95 citations

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 64 citations

Ide Analogues, Viral Hepatitis, Medicine +10